Vision & Mission
The Pediatric Praziquantel Consortium is an international partnership that works on a not-for-profit basis in the field of drug research and development for schistosomiasis. This neglected tropical disease affects 258 million people worldwide, including 25 million preschool-age children that are currently lacking adequate treatment.
Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.
Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.
To accomplish its mission:
- The Consortium combines some of the best science and most experienced public and private partners to develop and provide a new pediatric formulation of praziquantel to treat schistosomiasis.
- The Consortium operates through an innovative approach that engages new partners as needed. Beyond the partners contributing expertise and resources, the Consortium consults international academics, experts from endemic countries, funding agencies, the WHO and non-governmental organizations.
- The pediatric formulation developed by the Consortium will use small, orally dispersible tablets with acceptable taste properties, which withstands the challenges presented by a tropical climate.
- The clinical program is set up in line with FDA recommendations for pediatric development. It has been designed with the help of international experts, including clinicians from endemic countries, and it has been discussed with representatives from endemic country regulatory authorities.
- The Consortium pro-actively ‘builds capacity’ in endemic countries to support drug availability, affordability and accessibility to patients.